Drug intelligence / Profile preview

dextran 70 + hypromellose

Development stage: Unknown
Lead developer: Alcon
Modality: Small Molecules
Administration: Ophthalmic

Overview

Bion Tears is a preservative-free lubricant eye drop solution developed by Alcon for the relief of dry eye symptoms. It utilizes the Duasorb water-soluble polymeric system, consisting of dextran 70 (0.1%) and hypromellose (0.3%), which mimics the action of natural tears to provide hydration and protection to the ocular surface. The formulation is specifically designed for patients with moderate to severe dry eye who may be sensitive to preservatives like benzalkonium chloride. In 2024, OcuMension Therapeutics acquired the commercialization rights for Bion Tears in China as part of a broader portfolio deal with Alcon.

Brand names: Bion Tears
Other names: Bion Tears Lubricant Eye Drops

Beyond the preview

Go deeper on dextran 70 + hypromellose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dextran 70 + hypromellose.

Explore the full profile